Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rAAV-sh-Ngn3
- Development stage
- Unknown
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Parenteral
01
Overview
rAAV-sh-Ngn3 is a recombinant adeno-associated virus (rAAV) vector designed to deliver short hairpin RNA (shRNA) for the targeted knockdown of Neurogenin-3 (Ngn3) expression. Ngn3 is a basic helix-loop-helix (bHLH) transcription factor that serves as a master regulator for the differentiation of endocrine progenitor cells in the pancreas and the intestine. By leveraging the RNA interference (RNAi) pathway, rAAV-sh-Ngn3 facilitates the sequence-specific degradation of Ngn3 mRNA, thereby inhibiting the production of the Ngn3 protein. This construct is extensively used as a research tool in preclinical models to investigate the developmental requirements of the endocrine pancreas, study the plasticity of pancreatic cell types, and model conditions of Ngn3 deficiency. While Ngn3 overexpression is a common strategy in regenerative medicine for diabetes, the shRNA-mediated knockdown approach is primarily utilized to elucidate gene function and regulatory networks in developmental biology.
- Other names
- rAAV-shRNA-Ngn3rAAV-shRNA-Ngn-3rAAV-shRNA-Ngn 3AAV-shRNA-Ngn3AAV-shRNA-Ngn-3AAV-shRNA-Ngn 3
02
Targets
NEUROG3 (Neurogenin-3)
Beyond the preview
Go deeper on rAAV-sh-Ngn3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rAAV-sh-Ngn3.